Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPEAT: Lenalidomide, Cyclophosphamide, Prednisone in Multiple Myeloma
NCT01352338Phase 2Completed
- Start
- Aug 2011
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM). Primary endpoint: Phase 1 Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT) at 29 days. Started Aug 2011; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01352338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352338.